PMID- 16295525
OWN - NLM
STAT- MEDLINE
DCOM- 20051223
LR  - 20191109
IS  - 1740-2522 (Print)
IS  - 1740-2530 (Electronic)
IS  - 1740-2522 (Linking)
VI  - 12
IP  - 3
DP  - 2005 Sep
TI  - The diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix 
      metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and 
      C-reactive protein in patients with erosive and non-erosive rheumatoid arthritis.
PG  - 197-202
AB  - OBJECTIVE: To compare the diagnostic utility of laboratory variables, including 
      matrix metalloproteinase-3 (MMP-3), anticyclic citrullinated peptide (CCP) 
      antibodies, rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and 
      C-reactive protein (CRP) in patients with erosive and non-erosive rheumatoid 
      arthritis (RA). METHODS: We assembled a training set, consisting of 60 patients 
      with RA, all fulfilling the revised criteria of the American College of 
      Rheumatology. A commercial enzyme linked immunosorbent assay (ELISA) was used 
      both to test for anti-CCP antibodies (second generation ELISA kit) and MMP; RF 
      were detected by latex-enhanced immunonephelometric assay. CRP was measured by 
      latex turbidimetric immunoassay. RESULTS: The levels of anti-CCP antibody titers 
      and ESR were significantly higher in patients with erosive disease than those in 
      non-erosive RA patients (p < 0.001 and 0.0341) respectively. Moreover, a higher 
      frequency of elevated titers of anti-CCP antibodies was found in RA patients with 
      erosions compared to patients with non-erosive RA (78.3% vs. 43.2% respectively). 
      The ROC curves of anti-CCP passed closer to the upper left corner than those 
      other markers and area under the curve (AUC) of anti-CCP was significantly larger 
      than AUC of other markers (0.755 for anti-CCP, 0.660 for ESR, 0.611 for CRP, 
      0.577 for RF, and 0.484 for MMP-3 female). A positive predictive value was higher 
      for anti-CCP antibodies in comparison to other markers. We did not find 
      significant statistical correlation between anti-CCP antibody titers and 
      inflammatory markers such as ESR or CRP. However, we confirmed the correlation of 
      elevated titers of anti-CCP antibodies and RF in both groups of patients whereas 
      the degree of correlation was more significant in non-erosive patients. 
      CONCLUSION: The results of our study suggest that the presence of elevated 
      anti-CCP antibody titers have better diagnostic performance than MMP-3, RF, CRP 
      and ESR in patients with erosive RA.
FAU - Shovman, O
AU  - Shovman O
AD  - Center for Autoimmune Diseases, Department of Medicine B, Sheba Medical Center, 
      Israel.
FAU - Gilburd, B
AU  - Gilburd B
FAU - Zandman-Goddard, G
AU  - Zandman-Goddard G
FAU - Sherer, Y
AU  - Sherer Y
FAU - Orbach, H
AU  - Orbach H
FAU - Gerli, R
AU  - Gerli R
FAU - Shoenfeld, Y
AU  - Shoenfeld Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Egypt
TA  - Clin Dev Immunol
JT  - Clinical & developmental immunology
JID - 101183692
RN  - 0 (Autoantibodies)
RN  - 0 (Biomarkers)
RN  - 0 (Peptides, Cyclic)
RN  - 0 (cyclic citrullinated peptide)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 9009-79-4 (Rheumatoid Factor)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Aged
MH  - Arthritis, Rheumatoid/blood/*diagnosis/enzymology/*immunology
MH  - Autoantibodies/*blood
MH  - Biomarkers/blood
MH  - Blood Sedimentation
MH  - C-Reactive Protein/metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 3/blood
MH  - Middle Aged
MH  - Peptides, Cyclic/*immunology
MH  - Predictive Value of Tests
MH  - Rheumatoid Factor/blood
MH  - Sensitivity and Specificity
PMC - PMC2275423
EDAT- 2005/11/22 09:00
MHDA- 2005/12/24 09:00
PMCR- 2005/09/01
CRDT- 2005/11/22 09:00
PHST- 2005/11/22 09:00 [pubmed]
PHST- 2005/12/24 09:00 [medline]
PHST- 2005/11/22 09:00 [entrez]
PHST- 2005/09/01 00:00 [pmc-release]
AID - S1740252205000260 [pii]
AID - 10.1080/17402520500233510 [doi]
PST - ppublish
SO  - Clin Dev Immunol. 2005 Sep;12(3):197-202. doi: 10.1080/17402520500233510.